9 May 2016 - The FDA has been on a streak of late. Over the weekend, the agency approved the first new treatment for ALS, or Lou Gehrig's disease, since 1995 (Mitsubishi Tanabe Pharma's Radicava).
The brings the total number of new medicine approvals up to 20 so far this year.
So how does that stack up against the FDA's historical performance? Consider this: there were 22 new treatments cleared for the market in all of 2016.